Sector News

Novo opens ‘greenfield’ insulin plant in Russia

April 13, 2015
Life sciences
Novo Nordisk has opened a new manufacturing facility in Russia for formulation and filling of modern insulin destined for the treatment of diabetes.
 
Located at the Technopark Grabtsevo in the Kaluga region of Russia, the plant is the first and only greenfield facility for manufacturing modern insulin in the county, with environmental targets for CO² emission, water consumption and use of energy, according to the Danish drugmaker.
 
Around 10 million people in Russia are thought to have diabetes, and Novo says its move will ensure availability of high-quality modern insulins to patients. 
 
“I am convinced that the new facility will have a significant impact on improving the quality of life for people with diabetes in Kaluga as well as in the rest of Russia,” said Kaluga Region Governor, Anatoly Artamonov.
 
Novo currently also has production sites in Denmark, Brazil, China, France and the US.
 
By Selina McKee
 
Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.